Genomas and Institute of Living Among Organizers of Pharmacogenetics Symposium at 2009 Annual Meeting of the American Psychiatric A...( Field Moving Toward Genotype-Guided P...)

Field Moving Toward Genotype-Guided Psychotropic Therapy

SAN FRANCISCO, May 21 /PRNewswire/ -- Gualberto Ruano, M.D., Ph.D., President of Genomas, and Director of Genetics Research at Hartford Hospital and Simon Kung, M.D., Assistant Professor of Psychiatry at the Mayo Clinic will co-chair a symposium, "Emerging Clinical Applications of Genotype-Guided Psychotropics for Depressive Disorders," at the annual meeting of the American Psychiatric Association.

"Genotyping is at a point where it could be used to help guide therapeutic choices," said the Mayo Clinic's Dr. Kung. "It's fitting that Mayo Clinic, Genomas and Institute of Living/Hartford Hospital partnered on today's symposium since these institutions are among the true innovators in delivering personalized medicine to patients."

Papers presented at today's symposium were:

Greater Utilization of Psychiatric Services is Associated with Pharmacogenetic Variation and Metabolism Deficiencies

Gualberto Ruano, M.D., Ph.D., and John W. Goethe, M.D.

Genomas Inc. and Institute of Living/Hartford Hospital, Hartford, CT

Cytochrome P-450 2D6, 2C19, and Serotonin Transporter Genotyping for Depressed Inpatients at the Mayo Clinic Mood Disorders Unit

Simon Kung, M.D.

Mayo Clinic, Rochester, MN

Pharmacogenetic Testing in Psychiatry: Early Adopters' Attitudes and Practices

Jinger G. Hoop, M.D., M.F.A.

Medical College of Wisconsin, Milwaukee, WI

The Serotonin Transporter Gene (SLC6A4): Understanding Variability and Enhancing the Clinical Utility of Genotyping

David Mrazek, M.D.

Mayo Clinic, Rochester, MN

Dr. Ruano presented results from a study that showed a significant link between certain genetic variations and length of stay and re-hospitalization rate
'/>"/>